Olesya Zinych
Principal investigator
Contact
Phone
Main: +380 442541284
Mob: +380 976444044
FAX Number
Main: +380444301036
Primary: o.v.zinych@gmail.com
Facility Affiliation
State Institution “Institute of Endocrinology and Metabolism named after V.P. Komisarenko of National Academy of Medical Scienceof Ukraine”
Department of Aging endocrinology and Clinical Pharmacology
69 Vyshhorodska Str., Kyiv, 04114, Ukraine
Education and Training (List all Colleges, Universities and Medical Schools attended, postdoctoral/fellowship training, board certification/medical license)
|
Name and Location of Institution (City, State or Province and Country) |
Degree and Year Awarded |
Area of Study |
|
P.L. Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine |
Advanced course, the high category, 2015 |
Endocrinology |
|
SI V.P.Komisarenko Institute of Endocrinology and Metabolism of Academy of Medical Sciences of Ukraine, Kyiv, Ukraine |
DMSc, 2014 |
General Medicine |
|
P.L. Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine |
Advanced course, the first category, 2009 |
Endocrinology |
|
SI V.P.Komisarenko Institute of Endocrinology and Metabolism of Academy of Medical Sciences of Ukraine, Kyiv, Ukraine |
PhD, 2007 |
General Medicine |
|
P.L. Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine |
Endocrinologist, 2004 |
Endocrinology |
|
National Medical University, Kyiv, Ukraine |
MD From: 1997 To: 2003 |
General Medicine |
Professional Experience
|
Position/Title |
Name and Location of Institution (City, State or Province and Country) |
Dates (Start/Stop Dates as applicable) |
| Current
Acting Head of Department of Aging endocrinology and Clinical Pharmacology |
State Institution V.P.Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine, Unit of Clinical Pharmacology and Pharmacotherapy of Endocrine Diseases, Department of Age Pathology and Clinical Pharmacology, Kyiv, Ukraine |
2019 – ongoing |
| Leadresearch fellow |
State Institution V.P.Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine, Unit of Clinical Pharmacology and Pharmacotherapy of Endocrine Diseases, Department of Age Pathology and Clinical Pharmacology, Kyiv, Ukraine |
2017-2019 |
| Senior research fellow |
State Institution V.P.Komisarenko Institute of Endocrinology and Metabolism of National Academy of Medical Sciences of Ukraine, Department of Age Pathology and Clinical Pharmacology (Unit of Department of Clinical Pharmacology and Pharmacotherapy of Endocrine Diseases), Kyiv, Ukraine |
2011-ongoing |
| Previous
Junior research fellow |
SI V.P.Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine, of Department of Clinical Pharmacology and Pharmacotherapy of Endocrine Diseases, Kyiv, Ukraine |
2005-2010 |
| Physician |
SI V.P.Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine, of Department of Clinical Pharmacology and Pharmacotherapy of Endocrine Diseases, Kyiv, Ukraine |
2004-2005 |
Training
GCP Training
NIDA Clinical Trials Network (National Institute of Drug Abuse)
|
Date Started: Feb 21, 2011 |
Date Completed: Feb 21, 2011 |
The State Expert Center of the Ministry of Health of Ukraine
|
Date Started: Oct 4, 2012 |
Date Completed: Oct 5, 2012 |
Brookwood International Academy
|
Date Started: Sep 6, 2016 |
Date Completed: Sep 6, 2016 |
The State Expert Center of the Ministry of Health of Ukraine
|
Date Started: Oct 18, 2017 |
Date Completed: Oct 18, 2017 |
The Global Health Network
|
Date Started: Feb 8, 2018 |
Date Completed: Feb 8, 2018 |
Research Experience
Phase II, Phase III, Phase IV
Indication
- Diabetes Mellitus
- Diabetes Complications
- Dyslipidemias
- Obesity
Studies
1.NCT00968812
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
2.NCT01032629
CANVAS – CANagliflozin cardioVascular Assessment Study
Phase III: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors
Interventional: Completed
3.NCT01106651
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
4.NCT01106677
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis – DPP-4 Inhibitor Comparator Trial)
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
5.NCT01809327
A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
6.NCT01858532
Study Of Diabetic Nephropathy With Atrasentan
Phase III: Diabetic Nephropathy
Interventional: Active, not recruiting
7.NCT01989754
A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
Phase IV: Diabetes Mellitus, Type 2, Albuminuria
Interventional: Completed
8.NCT01768559
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
Phase III: Type 2 Diabetes
Interventional: Completed
9.NCT01494987
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Phase III: Type 2 Diabetes Mellitus
Interventional: Completed
10.NCT01472185
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Phase III: Type 2 Diabetes Mellitus
Interventional: Completed
11.NCT01555164
A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
Phase III: Type 2 Diabetes Mellitus
Interventional: Completed
12.NCT01455896
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
Phase III: Type 2 Diabetes
Interventional: Completed
13.NCT00332488
Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
14.NCT01544881
Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes
Phase I: Type 1 Diabetes Mellitus
Interventional: Completed
15.NCT01849289
A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes
Phase III: Diabetes, Diabetes Mellitus, Type 2
Interventional: Completed
16.NCT01513590
A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes
Phase III: Diabetes, Diabetes Mellitus, Type 2
Interventional: Completed
17.NCT01533428
A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)
Phase III: Diabetic Peripheral Neuropathy, Pain
Interventional: Completed
18.NCT01459809
Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
19.NCT01897532
Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
Phase IV: Diabetes Mellitus, Type 2
Interventional: Completed
20.NCT01455896
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
Phase III: Type 2 Diabetes
Interventional: Completed
21.NCT02863419
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
Phase III: Diabetes, Diabetes Mellitus, Type 2
Interventional: Completed
22.NCT01481116
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Phase III: Diabetes Mellitus, Type 2
Interventional: Terminated
23.NCT00690456
Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes
Phase III: Diabetes Mellitus, Type 2
Interventional: Terminated
24.NCT00736099
Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
25.NCT00740051
A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
26.NCT00362323
Fenofibrate and Metformin Fixed Combination vs Metformin – FAME METFO
Phase III: Dyslipidemia/Glucose Metabolism Disorder
Interventional: Completed
27.NCT00332488
Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
28.NCT00483730
Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)
Phase III: Symptomatic Diabetic Peripheral Polyneuropathy
Interventional: Completed
29.NCT03071692
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
Phase III: Type2 Diabetes, Dyslipidemia
Interventional: Recruiting
30.NCT03315143
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
Phase III: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Interventional: Recruiting
31.NCT03548987
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Phase III: Metabolism and Nutrition Disorder, Obesity
Interventional: Recruiting
Publications
In total – more than 120
Vadym Korpachev
Investigator
| Academic title: | MD,PhD, Doctor of medical science, professor |
| Present position | Chief Researcher of the Age Endocrinology and Clinical Pharmacology Department of the State Institution “Institute of endocrinology and metabolism n.a. V.P. Komisarenko of the National Academy of Medical Science of Ukraine” |
| Business address | 69, Vyshgorodska str., Kiev, 04114, Ukraine |
| Relevant education
(Type of degree and year of competition) |
Kyiv medical Institute, Kyiv, USSR
MD, 1968 |
| Relevant previous positions
(Name of institution and/or organization and year) |
Head of the Department of Clinical Pharmacology and Pharmacotherapy of Endocrine Disease, State Institution V.P. Komissarenko Institute of Endocrinology and Metabolism of AMS of Ukraine, 1989-2019;
Senior Research Scientist of State Institution “Institute of endocrinology and metabolism named after V.Komisarenka of the Academy of Medical Science of Ukraine”, 1982-1989; Junior Research Scientist of State Institution “Institute of endocrinology and metabolism named after V.Komisarenka of the Academy of Medical Science of Ukraine”, 1972-1982 Post Graduate Student of State Institution “Institute of endocrinology and metabolism named after V. Komisarenka of the Academy of Medical Science of Ukraine”, 1968-1972 |
| Relevant job related training
(Year of attendance, type of qualification, e.g., specialist courses) |
State Institution “Institute of endocrinology and metabolism named after V.Komisarenka of the Academy of Medical Science of Ukraine”, Professor, Endocrinology, 2010
State Institution “Institute of endocrinology and metabolism named after V.Komisarenka of the Academy of Medical Science of Ukraine”, DocMedSc, Endocrinology, 1992 State Institution “Institute of endocrinology and metabolism named after V.Komisarenka of the Academy of Medical Science of Ukraine”, PhD, endocrinology, 1972 |
| Relevant clinical trial and research experience | PI: K-877-302, 2017 – ongoing
SI: EFC14875, 2018 – ongoing SI: NN9536-4376, 2018 – ongoing PI: GLP116174, 2015 – 2018 PI: BI1218.22, 2015-2018 PI: M11-352, 2015-2018 SI: NN9924-4224, 2016 – 2018 PI: ITCA650CLP107, 2014-2016 PI: MKC-TI-134, 2014-2015 PI: NN 1250-3587, 2013 – 2014 PI: 28431754DIA-3011, 2012-2015 PI: 28431754DIA-3011, 2012-2015 PI: NN 2211-3916, 2012 – 2013 PI: MKC-TI-171,2012-2013 PI: GS-US-259-0110, 2012-2013 PI: GS-US-259-0131, 2012-2013 PI: GS-US-259-0147, 2012-2013 PI: MKC-TI-175, 2012-2013 PI: MKC-TI-171, 2011-2013 PI: GS-US-259-0147, 2012-2013 PI: ТАК-875_304,2012-2014 PI: 28431754 DIA 3008, 2011-2017 PI: 28431754 DIA 3010,2011-2013 PI: 28431754 DIA 3009, 2011-2013 PI: NN 5401-3940, 2011 – 2012 PI: 28431754 DIA 3006, 2011-2012 PI: EFC12626, 2011-2013 PI: NN 1250-3672, 2010 – 2011 |
| GCP training
(name of course,Date of GCP completion, provider of GCP course) |
“ICH Good Clinical Practice E6 (R2)”, Certificate No. 354001, The Global Health Network, online training,
08 feb 2018 Good Clinical Practice (GCP). Clinical trial regulation”, Certificate No. 3227, The State Expert Center of the MoH of Ukraine, Kyiv, Ukraine, 29 nov 2017 Essential Good Clinical Practice”, Brookwood International Academy, 06 sep 2016 |
Nataliya Kushnarova
Investigator, Study Coordinator
| Phone | +380 442541284 |
| natalijakush@gmail.com | |
| Facility Affiliation | Institute of Endocrinology and Metabolism named after Komissarenko Vyshhorodskaya Street 69, Kiev, 04114, Ukraine Aging enocrinology and clinical pharmacology |
| Medical Education | National Medical University O.O. Bogomolets
Ukraine Year Started: 1994 Year Finished: 2000 |
| Professional Experience | Senior Research Fellow Institute of Endocrinology and Metabolism named after Komissarenko Ukraine From: 2016 To: Present Research Fellow From: 2014 To: 2015 Junior Reserch Fellow From: 2006 To: 2013 |
| Medical Specialty |
301 Issue Date: Dec 27, 2010 Expiration Date: Sep 21, 2020 |
| GCP Training | Brookwood International Academy
Date Started: Sep 5, 2016 Date Completed: Sep 5, 2016 Abbvie Date Started: Jun 26, 2014 Date Completed: Jun 26, 2014 The State Expert Center of the Ministry of Health of Ukraine Date Started: Oct 4, 2012 Date Completed: Oct 5, 2012 NIDA Clinical Trials Network (National Institute of Drug Abuse) Date Started: Apr 26, 2011 Date Completed: Apr 26, 2011 The Global Health Network Date Started: Feb 8, 2018 Date Completed: Feb 8, 2018 The State Expert Center of the Ministry of Health of Ukraine Date Started: Oct 18, 2017 Date Started: Oct 18, 2017 |
| Research Experience | Phase II, Phase III, Phase IV |
| Indication |
|
NCT01463397
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Phase II: Neuropathic Pain
Interventional: Completed
NCT01768559
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
Phase III: Type 2 Diabetes
Interventional: Completed
NCT01517412
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Phase III: Type 2 Diabetes Mellitus
Interventional: Completed
NCT01147250
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Phase III: Acute Coronary Syndrome
Interventional: Completed
NCT01494987
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Phase III: Type 2 Diabetes Mellitus
Interventional: Completed
NCT01472185
Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus
Phase III: Type 2 Diabetes Mellitus
Interventional: Completed
NCT01555164
A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
Phase III: Type 2 Diabetes Mellitus
Interventional: Completed
NCT01455896
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
Phase III: Type 2 Diabetes
Interventional: Completed
NCT01858532
Study Of Diabetic Nephropathy With Atrasentan
Phase III: Diabetic Nephropathy
Interventional: Terminated
NCT01459133
Single Site, Single Subject, Treatment IND With Mannkind Corporation’s Technosphere Inhalation System
Diabetes
Interventional: Withdrawn
NCT00332488
Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
NCT01544881
Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes
Phase I: Type 1 Diabetes Mellitus
Interventional: Completed
NCT01849289
A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes
Phase III: Diabetes, Diabetes Mellitus, Type 2
Interventional: Completed
NCT01620489
Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment
Phase III: Diabetes, Diabetes Mellitus, Type 2
Interventional: Completed
NCT01513590
A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes
Phase III: Diabetes, Diabetes Mellitus, Type 2
Interventional: Completed
NCT01533428
A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)
Phase III: Diabetic Peripheral Neuropathy, Pain
Interventional: Completed
NCT01459809
Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
NCT00379769
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
NCT01897532
Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
Phase IV: Diabetes Mellitus, Type 2
Interventional: Completed
NCT01032629
CANVAS – CANagliflozin cardioVascular Assessment Study
Phase III: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors
Interventional: Completed
NCT01809327
A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
NCT00968812
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
NCT01106651
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
NCT01106677
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis – DPP-4 Inhibitor Comparator Trial)
Phase III: Diabetes Mellitus, Type 2
Interventional: Completed
NCT01989754
A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
Phase IV: Diabetes Mellitus, Type 2, Albuminuria
Interventional: Completed
NCT01455896
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
Phase III: Type 2 Diabetes
Interventional: Completed
NCT02863419
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
Phase III: Diabetes, Diabetes Mellitus, Type 2
Interventional: Completed
NCT03315143
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
Phase III: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Interventional: Active, not recruiting
NCT03548987
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Phase III: Metabolism and Nutrition Disorder, Obesity
Interventional: Active, not recruiting
NCT03882970
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
Phase III: Type 2 Diabetes Mellitus
Interventional: Active, not recruiting
NCT03819153
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
Phase III: Diabetes Mellitus, Type 2
Interventional: Recruiting
NCT01897532
Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
Phase IV: Diabetes Mellitus, Type 2
Interventional: Completed
NCT03071692
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
Phase III: Type2 Diabetes, Dyslipidemia
Interventional: Recruiting
Alla Kovalchuk
Investigator
| Academic title: | PhD |
| Present position | Leading research worker of the Age Endocrinology and Clinical Pharmacology Department of the State Institution “Institute of endocrinology and metabolism n.a. V.P. Komisarenko of the National Academy of Medical Science of Ukraine” |
| Business address | 69, Vyshgorodska str., Kiev, 04114, Ukraine |
| Relevant education
(Type of degree and year of competition) |
National medical university, Ukraine
MD, 1988 |
| Relevant previous positions
(Name of institution and/or organization and year) |
Senior Research Scientist of State Institution “Institute of endocrinology and metabolism named after V.Komisarenka of the Academy of Medical Science of Ukraine”, 2007-2013;
Research Scientist of State Institution “Institute of endocrinology and metabolism named after V.Komisarenka of the Academy of Medical Science of Ukraine”, 1993-2006; Junior Research Scientist of State Institution “Institute of endocrinology and metabolism named after V.Komisarenka of the Academy of Medical Science of Ukraine”, 1988-1993; |
| Relevant job related training
(Year of attendance, type of qualification, e.g., specialist courses) |
State Institution “Institute of endocrinology and metabolism named after V.Komisarenka of the Academy of Medical Science of Ukraine”, PhD, medicine, 2009
National Medical Academy of Postgraduate Education, Advanced course, Ukraine, 2011, Endocrinology National Medical Academy of Postgraduate Education, Advanced course, Ukraine, 2013, Endocrinology the high category endocrinologist |
| Relevant clinical trial and research experience | SI: K-877-302, 2017 – ongoing
SI: NN9536-4376, 2018 – ongoing SI: EFC14875, 2018 – ongoing SI: GLP116174, 2015 – 2018 SI: BI1218.22, 2015-2018 SI: NN9924-4224, 2016 – 2018 SI: ITCA650CLP107, 2014-2016 SI: NN 1250-3587, 2013 – 2014 SI: 28431754DIA-3011, 2012-2015 SI: 28431754DIA-3011, 2012-2015 SI: GS-US-259-0110, 2012-2013 SI: GS-US-259-0131, 2012-2013 SI: MKC-TI-175, 2012-2013 SI: MKC-TI-171, 2011-2013 SI: ТАК-875_304,2012-2014 SI: 28431754 DIA 3008, 2011-2017 SI: 28431754 DIA 3010,2011-2013 SI: 28431754 DIA 3009, 2011-2013 SI: NN 5401-3940, 2011 – 2012 SI: 28431754 DIA 3006, 2011-2012 SI: EFC12626, 2011-2013 SI: NN 1250-3672, 2010 – 2011 |
| GCP training
(name of course,Date of GCP completion, provider of GCP course) |
ICH Good Clinical Practice E6 (R2)”, Certificate No. 354315, The Global Health Network, online training, 09 feb 2018
Good Clinical Practice (GCP). Clinical trial regulation”, Certificate No. 3044, The State Expert Center of the MoH of Ukraine, Kyiv, Ukraine, 18 oct 2017 Good Clinical Practice (GCP). Legal and Regulatory Requirements and Ethical Aspects of Clinical Trial Conducting”, Certificate No. 032, The State Expert Center of the MoH of Ukraine, Kyiv, Ukraine, 29 nov 2014 |
Olha Prybyla
Investigator
| Present Position: | Junior Research Scientist of the Age Endocrinology and Clinical Pharmacology Department of the State Institution “Institute of endocrinology and metabolism n.a. V.P. Komisarenko of the National Academy of Medical Science of Ukraine”, |
| Business Address: | 69, Vyshgorodska Str., Kyiv, 04114 Ukraine |
| Relevant Education: (type of degree and year when awarded) |
MD, National Medical Universitat, Kyiv, Ukraine, 2011 |
| Relevant Previous Positions: (name of institution and/or organisation and year) |
Junior Research Scientist of State Institution “Institute of endocrinology and metabolism named after V.Komisarenka of the Academy of Medical Science of Ukraine”, 2012-present time |
| Relevant Job Related Training: (year of completion, type of qualification; e.g. specialist courses) |
Kyiv Medical Academy of Postgraduate Education, Ukraine, 2012, Endocrynology
National Medical Academy of Postgraduate Education, Advanced course, Ukraine, 2016, Endocrinology – the second category endocrinologist National Medical Academy of Postgraduate Education, Advanced course, Ukraine, 2018, Endocrinology – the first category endocrinologist |
| Relevant Clinical Trial(s) and Research Experience: | SI: K-877-302, 2017 – ongoing
SI: NN9536-4376, 2018 – ongoing SI: EFC14875, 2018 – ongoing SI: BI1218.22, 2015-2018 SI: NN9924-4224, 2016 – 2018 SI: ITCA650CLP107, 2014-2016 SI: MKC-TI-134, 2014-2015 SI: NN 1250-3587, 2013 – 2014 |
| Documentation of GCP training (The name of GCP training; its provider and year of completion must be stated in the CV and/or a certificate of GCP training must be enclosed. The provider of GCP training can be internal, external, NN clinical staff ect.) |
“ICH Good Clinical Practice E6 (R2)”, Certificate No. 354281, The Global Health Network, online training,
09 feb 2018 “Good Clinical Practice (GCP). Clinical trial regulation”, Certificate No. 3037, The State Expert Center of the MoH of Ukraine, Kyiv, Ukraine, 18 oct 2017 “Essential Good Clinical Practice”, Brookwood International Academy, online training, 05 sep 2016 |
Kateryna Shyshkan-Shyshova
Investigator
| Present position | Junior research fellow, State Institution V.P.Komisarenko Institute of Endocrinology and Metabolism of National Academy of Medical Sciences of Ukraine, Department of Age Pathology and Clinical Pharmacology Kyiv, Ukraine,
2015 – ongoing |
| Business address | 69, Vyshgorodska str., Kiev, 04114, Ukraine |
| Relevant education
(Type of degree and year of competition) |
National Medical University named after O.O. Bohomolets, Kyiv, Ukraine MD, 2008 |
| Relevant previous positions
(Name of institution and/or organization and year) |
Laboratory assistant with higher education, State Institution V.P.Komisarenko Institute of Endocrinology and Metabolism of National Academy of Medical Sciences of Ukraine, Department of Diabetology and Experimental Endocrinology, 2008-2014
Intern, National Medical University, Ukraine Department of Internal Diseases, 2008-2010 |
| Relevant job related training
(Year of attendance, type of qualification, e.g., specialist courses) |
National Medical Academy of Postgraduate Education, Kyiv, Ukraine, Advanced course, Endocrinology (2013) |
| Relevant clinical trial and research experience | SI: NN9924-4224, 2016
SI: K-877-302, 2017-on-going SI: EFC14875, 2017-on-going SI: NN9536-4376, 2018 – on-going SI: I8F-MC-GPGH, 2019 – on-going |
| GCP training
(name of course,Date of GCP completion, provider of GCP course) |
GCP, The State Expert centre of MoH of Ukraine, 18-Oct-2017
GCP, The State Expert centre of MoH of Ukraine, 16-Feb-2016 |
Link to: Get in touch
Any questions? Get in touch with us!
Learn more about changes in hormone levels with age, make an appointment, detailed information about hospitalization
Link to: Get in touch
Any questions? Get in touch with us!
Learn more about changes in hormone levels with age, make an appointment, detailed information about hospitalization